Алексеева Л.И. Остеоартроз: проблема века. Медицинский совет, 2013, 5: 78-80.

Кашеварова Н.Г., Зайцева Е.М., Пушкова О.В., Смирнов А.В., Алексеева Л.И. Факторы прогрессирования остеоартроза коленных суставов (5-летнее проспективное наблюдение). Остеопороз и остеопатии, 2013, 2: 9-11.

Насонова В.А., Цветкова Е.С. Фармакотерапия остеоартроза. Лечащий врач, 2004, 7: 22-24.

Чичасова Н.В. Проблема боли при остеоартрозе. Лечащий врач, 2007, 2: 31-34.

Altman RD Glucosamine therapy for knee osteoarthritis: pharmacokinetic considerations. Expert Rev Clin Pharmacol, 2009 Jul, 2(4): 359-71.

Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet, 2011 Jun 18, 377(9783): 2115-26.

Bruyère O, Cooper C, Pelletier JP, Branco J, Luisa Brandi M, Guillemin F, Hochberg MC, Kanis JA, Kvien TK, Martel-Pelletier J, Rizzoli R, Silverman S, Reginster JY. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum, 2014 Dec, 44(3): 253-63.

Bruyere O, Pavelka K, Rovati LC, Deroisy R, Olejarova M, Gatterova J, Giacovelli G, Reginster JY. Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause, 2004 Mar-Apr, 11(2): 138-43.

Bruyere O, Pavelka K, Rovati LC, Gatterová J, Giacovelli G, Olejarová M, Deroisy R, Reginster JY. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage, 2008 Feb, 16(2): 254-60.

Chiusaroli R, Piepoli T, Zanelli T, Ballanti P, Lanza M, Rovati LC, Caselli G Experimental Pharmacology of Glucosamine Sulfate. Int J Rheumatol, 2011, 2011: 939265.

Eriksen P, Bartels EM, Altman RD, Bliddal H, Juhl C, Christensen R. Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials. Arthritis Care Res (Hoboken), 2014 Dec, 66(12): 1844-55.

European Medicines Agency CPMP/EWP/784/97 Rev. 1. Guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis. January 2010.

Giordano N, Fioravanti A, Panagiotas P, Montella A, Giorgi G, Nuti R The efficacy and tolerability of glucosamine sulfate in the treatment of knee osteoarthritis: A randomized, double-blind, placebo-controlled trial. Current Therapeutic Research, 2009 Jun, 70(3): 185-096.

Henrotin Y, Mobasheri A, Marty M. Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis? Arthritis Res Ther, 2012 Jan 30, 14(1): 201.

Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, Towheed T, Welch V, Wells G, Tugwell P; American College of Rheumato-logy American College of Rheumatology 2012 recommendations for the use of nonpharmaco-logic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken), 2012 Apr, 64(4): 465-74.

Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, Gunther K, Hauselmann H, Herrero-Beaumont G, Kaklamanis P, Lohmander S, Leeb B, Lequesne M, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Serni U, Swoboda B, Verbruggen G, Zimmerman-Gorska I, Dougados M; Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis, 2003 Dec, 62(12): 1145-55.

Lane NE, Brandt K, Hawker G, Peeva E, Schreyer E, Tsuji W, Hochberg MC OARSI-FDA initiative: defining the disease state of osteoarthritis. Osteoarthritis Cartilage, 2011 May, 19(5): 478-82.

Mazzuca SA, Brandt KD, Katz BP, Hanna MP, Melfi CA. Reduced utilization and cost of primary care clinic visits resulting from self-care education for patients with osteoarthritis of the knee. Arthritis Rheum, 1999, 42: 1267-73.

McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, Hawker GA, Henrotin Y, Hunter DJ, Kawaguchi H, Kwoh K, Lohmander S, Rannou F, Roos EM, Underwood M OARSI guidelines for the nonsurgical management of knee osteoarthritis. Osteoarthritis Cartilage, 2014 Mar, 22(3): 363-88.

Müller-Fassbender H, Bach GL, Haase W, Rovati LC, Setnikar I. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage, 1994 Mar, 2(1): 61-9.

National Clinical Guideline Centre Osteoarthritis: Care and Management in Adults. Clinical Guideline CG177, 2014.

Neogi T, Nevvit M, Niu J et al. Subchondral bone attrition may be a reflection of compartment-specific mechanical load: the MOST Study. Ann. Rheum. Dis., 2010, 69(5): 841-4.

Bruyère O, Cooper C, Pelletier JP, Maheu E, Rannou F, Branco J, Luisa Brandi M, Kanis JA, Altman RD, Hochberg MC, Martel-Pelletier J, Reginster JY. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum, 2016 Feb, 45(4 Suppl): S3-11.

Pereira D, Peleteiro B, Araújo J, Branco J, Santos RA, Ramos E. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthritis Cartilage, 2011 Nov, 19(11): 1270-85.

Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE, Gossett C. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet, 2001 Jan 27, 357(9252): 251-6.

Reginster JY, Neuprez A, Lecart MP, Sarlet N, Bruyere O. Role of glucosamine in the treatment for osteoarthritis. Rheumatol Int, 2012 Oct, 32(10): 2959-67.

Roman-Blas JA, Castañeda S, Largo R, Herrero-Beaumont G. Glucosamine sulfate for knee osteoarthritis: science and evidence-based use. Therapy, 2010 Nov, 7(6): 591-604. DOI: http:// dx.doi.org/10.2217/thy.10.67..
DOI: 10.2217/thy.10.67

Rovati LC Crystalline glucosamine sulfate in the only SYSADOA that decreases consumption of NSAIDs in knee osteoarthritis: results from the PEGASus cohort. Oral presentation; 2014 OARSI World Congress on Osteoarthritis, Paris, France, 24-27 April 2014.

Rovati LC, Girolami F, Persiani S. Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties. Ther Adv Musculoskelet Dis, 2012 Jun, 4(3): 167-80.

Simon RR, Marks V, Leeds AR, Anderson JW. A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals. Diabetes Metab Res Rev, 2011 Jan, 27(1): 14-27.

Stumpf JL, Lin SW. Effect of glucosamine on glucose control. Ann Pharmacother, 2006 Apr, 40(4): 694-8.

Uitterlinden EJ, Jahr H, Koevoet JL, Jenniskens YM, Bierma-Zeinstra SM, Degroot J, Verhaar JA, Weinans H, van Osch GJ. Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthritic cartilage explants. Osteoarthritis Cartilage, 2006 Mar, 14(3): 250-7.

Vaz A. Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthrosis of the knee in out-patients. Curr Med Res, 1982, 8: 145-9.

Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage, 2010 Apr, 18(4): 476-99.